The ARSB Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HT29 colorectal adenocarcinoma cells with targeted disruption of the ARSB gene encoding lysosomal arylsulfatase B. This heterogeneous pool of edited cells abolishes ARSB activity, providing a physiologically relevant loss-of-function model that mimics cellular heterogeneity in lysosomal storage disorders and tumor microenvironments.
The parental HT29 cell line is an adherent epithelial cell type originally isolated from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female in 1964, and it has since become a widely employed model for intestinal epithelial biology and colon cancer research. HT29 cells retain the capacity for enterocytic differentiation under defined culture conditions, making them particularly valuable for studies of colorectal tumorigenesis and epithelial barrier function. Their established use as a colorectal cancer model, combined with tractable genetic manipulation, positions HT29 cells as an ideal host for generating targeted gene disruptions to explore the interplay between lysosomal function and cancer progression.
ARSB encodes arylsulfatase B, a lysosomal sulfatase critically involved in the stepwise degradation of glycosaminoglycans, specifically catalyzing the hydrolysis of sulfate esters from dermatan sulfate and chondroitin sulfate. The enzyme’s activation depends on post-translational modification by the sulfatase-modifying factor SUMF1, and its expression is transcriptionally regulated by the master lysosomal biogenesis factors TFEB and MITF in response to nutrient starvation or lysosomal stress. Upon ARSB-mediated desulfation, the resulting partially degraded glycosaminoglycans are further processed by other lysosomal acid hydrolases, culminating in the release of inorganic sulfate and monosaccharides. In the knockout cells, the absence of arylsulfatase B activity leads to progressive lysosomal accumulation of undigested dermatan sulfate and chondroitin sulfate, which can disrupt lysosomal membrane integrity and alter the subcellular localization of lysosomal membrane proteins such as LAMP1 and LAMP2, thereby affecting lysosomal exocytosis and downstream signaling pathways.
Within the HT29 colorectal cancer background, ARSB knockout generates a dual-relevance model system that not only recapitulates the glycosaminoglycan storage pathology characteristic of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) but also provides a platform to dissect the emerging roles of lysosomal dysfunction in colorectal tumor biology. Accumulating evidence suggests that altered glycosaminoglycan metabolism and lysosomal stress can modulate cancer cell proliferation, migration, and epithelial-mesenchymal transitions, and the ARSB knockout HT29 polyclonal cells offer a unique tool to examine these processes in a colonic epithelial context. By serving as both a disease model for a lysosomal storage disorder and a perturbed metabolic state in colorectal cancer, these cells enable integrated investigations into how impaired lysosomal degradation influences cellular homeostasis and oncogenic potential.
These polyclonal knockout cells support diverse applications including mucopolysaccharidosis type VI disease modeling, enzyme replacement therapy testing, pharmacological chaperone screening, and mechanistic studies of glycosaminoglycan metabolism in colorectal cancer. Researchers can employ standard assays such as western blotting, arylsulfatase B activity measurements, dimethylmethylene blue assays for GAG accumulation, LAMP1/LAMP2 immunofluorescence, RT-qPCR, LysoTracker pH assessment, and cell migration/proliferation assays, as well as co-immunoprecipitation with SUMF1 and electron microscopy for storage vacuoles. For further information, please contact Ascent Research.
